Tier 2 — strong

Quercetin pharmacokinetics in humans

Young J Moon, Liang Wang, Robert DiCenzo, Marilyn E Morris
Biopharmaceutics & drug disposition 2008 29(4):205

Bibliography

PubMed
PMID 18241083
DOI
10.1002/bdd.605
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignHuman repeated-dose pharmacokinetic study with population modeling
ModelHuman intervention research
SampleHuman volunteers; sample size not stated in the indexed abstract
InterventionQuercetin aglycone 500 mg three times daily
DurationRepeated dosing with blood and urine sampling
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2008, this source examined forms, absorption and food sources. Design: Human repeated-dose pharmacokinetic study with population modeling. Sample/model: Human volunteers; sample size not stated in the indexed abstract. The exposure or intervention was Quercetin aglycone 500 mg three times daily. Follow-up or treatment period: Repeated dosing with blood and urine sampling.

Quercetin and conjugates showed re-entry concentration peaks consistent with enterohepatic recirculation; the modeled aglycone terminal half-life averaged 3.5 hours.

Pharmacokinetic parameters depend on the analyte and method. This is not a clinical-benefit trial, and the abstract does not establish a general dosing schedule.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Forms: Dihydrate, Phytosome, Liposomal and Glycosides. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Quercetin and conjugates showed re-entry concentration peaks consistent with enterohepatic recirculation; the modeled aglycone terminal half-life averaged 3.5 hours.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Quercetin aglycone 500 mg three times daily; Repeated dosing with blood and urine sampling.

What this study can and cannot tell us

  • Pharmacokinetic parameters depend on the analyte and method. This is not a clinical-benefit trial, and the abstract does not establish a general dosing schedule.
  • A change in blood exposure or a metabolic marker is not a demonstrated improvement in symptoms, disease events or lifespan. The tested formulation and co-administered medicines matter.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies
Lu Liu et al. · Food chemistry · 2025
Tier 2
Microbiological and Pharmacokinetic Aspects of a Water-Soluble Quercetin 3-O-rutinoside, EubioQuercetin: A Direct Comparison With Quercetin in In Vitro and Human Clinical Studies
Naoto Yamaguchi et al. · Journal of food science · 2025
Tier 2
Comparative Pharmacokinetics and Safety of a Micellar Chrysin-Quercetin-Rutin Formulation: A Randomized Crossover Trial
Afoke Ibi et al. · Antioxidants (Basel, Switzerland) · 2025
Tier 2
Enhanced Bioavailability and Pharmacokinetics of a Natural Self-Emulsifying Reversible Hybrid-Hydrogel System of Quercetin: A Randomized Double-Blinded Comparative Crossover Study
Ashil Joseph et al. · ACS omega · 2022

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology